Terns Pharmaceuticals, Inc. (TERN): Price and Financial Metrics
GET POWR RATINGS... FREE!
TERN POWR Grades
- Growth is the dimension where TERN ranks best; there it ranks ahead of 65.62% of US stocks.
- TERN's strongest trending metric is Sentiment; it's been moving down over the last 178 days.
- TERN's current lowest rank is in the Momentum metric (where it is better than 4.74% of US stocks).
TERN Stock Summary
- For TERN, its debt to operating expenses ratio is greater than that reported by only 7.04% of US equities we're observing.
- With a price/sales ratio of 379.52, TERNS PHARMACEUTICALS INC has a higher such ratio than 98.89% of stocks in our set.
- TERN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 6.86% of US stocks.
- If you're looking for stocks that are quantitatively similar to TERNS PHARMACEUTICALS INC, a group of peers worth examining would be UBX, BCYC, EFTR, DCPH, and VLN.
- Visit TERN's SEC page to see the company's official filings. To visit the company's web site, go to www.ternspharma.com.
TERN Valuation Summary
- In comparison to the median Healthcare stock, TERN's EV/EBIT ratio is 183.97% lower, now standing at -5.5.
- TERN's price/sales ratio has moved NA NA over the prior 26 months.
Below are key valuation metrics over time for TERN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TERN | 2023-03-17 | 379.5 | 2.1 | -6.5 | -5.5 |
| TERN | 2023-03-16 | 373.5 | 2.0 | -6.4 | -5.4 |
| TERN | 2023-03-15 | 346.4 | 1.9 | -5.9 | -4.9 |
| TERN | 2023-03-14 | 363.0 | 2.0 | -6.2 | -5.2 |
| TERN | 2023-03-13 | 352.4 | 1.9 | -6.0 | -5.0 |
| TERN | 2023-03-10 | 343.0 | 1.9 | -5.8 | -4.8 |
TERN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TERN has a Quality Grade of C, ranking ahead of 30.41% of graded US stocks.
- TERN's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows TERN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 0 | NA | -5.557 |
TERN Price Target
For more insight on analysts targets of TERN, see our TERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
TERN Stock Price Chart Interactive Chart >
TERN Price/Volume Stats
| Current price | $9.88 | 52-week high | $11.44 |
| Prev. close | $10.09 | 52-week low | $1.45 |
| Day low | $9.69 | Volume | 287,000 |
| Day high | $10.42 | Avg. volume | 289,660 |
| 50-day MA | $9.50 | Dividend yield | N/A |
| 200-day MA | $6.00 | Market Cap | 371.63M |
Terns Pharmaceuticals, Inc. (TERN) Company Bio
Terns Pharmaceuticals, Inc. operates as a biopharmaceutical company. The Company discovers and develops molecularly-targeted and oral molecule drugs for the treatment of liver disease and cancer. Terns Pharmaceuticals serves customers worldwide.
Latest TERN News From Around the Web
Below are the latest news stories about TERNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate TERN as an investment opportunity.
Investing in Terns Pharmaceuticals (NASDAQ:TERN) a year ago would have delivered you a 211% gainThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. On the other hand, if you... |
Terns Pharmaceuticals Provides Program Updates and Announces Participation at Upcoming March Investor ConferencesCompletes enrollment in Phase 2a DUET clinical trial of TERN-501 (THR-β agonist) as a treatment for NASH with top-line results expected in third quarter of 2023 On track to initiate U.S. clinical trial for TERN-701 (allosteric BCR-ABL inhibitor) in CML in second half of 2023; enrollment progress update from ongoing China Phase 1 trial expected at a major upcoming oncology conference IND-enabling activities for TERN-601 (oral GLP-1R agonist) ongoing; on track to initiate first-in-human clinical t |
TipRanks ‘Perfect 10’ List: 3 Top-Rated Stocks That Tick All the Right BoxesThis year started off gangbusters, with strong across-the-board gains for stocks in January – and it’s been followed in February by moderate losses, as stocks first leveled off and now are trending down. The market shifts have investors worried that last year’s volatility is still with us, making for an unpredictable market environment. And it has those same investors looking for a way to cut through the data ‘noise’ and find the right stocks for an unsettled time. TipRanks’ Smart Score is just |
Are You Looking for a Top Momentum Pick? Why Terns Pharmaceuticals, Inc. (TERN) is a Great ChoiceDoes Terns Pharmaceuticals, Inc. (TERN) have what it takes to be a top stock pick for momentum investors? Let's find out. |
Terns Pharmaceuticals to Participate in Guggenheim Healthcare Talks 2023 Oncology ConferenceFOSTER CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and non-alcoholic steatohepatitis (NASH), today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 2023 Oncology Conference on Thursday, February 9, 2023 at 10:10 a.m. |
TERN Price Returns
| 1-mo | -6.79% |
| 3-mo | 15.96% |
| 6-mo | 102.04% |
| 1-year | 225.00% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -2.95% |
| 2022 | 43.99% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...